Analisis Saham PT Delta Giri Wacana Tbk (DGWG) Per Q3 Desember 2025
Analisis mendalam saham PT Delta Giri Wacana Tbk (DGWG) per Q3 Desember 2025: Rekomendasi BUY dengan target harga Rp 500-600, didukung oleh pertumbuhan pendapatan kuat, ekspansi kapasitas agresif, dan dukungan pemerintah terhadap keamanan pangan.
Disclaimer:
Analisis ini bukan nasihat investasi. Saham berisiko tinggi—lakukan riset mandiri (DYOR - Do Your Own Research) dan konsultasi dengan penasihat keuangan berlisensi sebelum mengambil keputusan. Hasil masa lalu tidak menjamin kinerja masa depan.
Tanggal Analisis: 7 Januari 2026
Harga Saat Ini: Rp 408 per lembar
Ticker: DGWG (Bursa Efek Indonesia)
Nama Perusahaan: PT Delta Giri Wacana Tbk
Sektor: Industri Proses - Bahan Kimia Pertanian (Agricultural Chemicals, Agro Input, Food Security)
Nilai Pasar: Rp 2.4 Triliun (estimated)
Jumlah Saham Beredar: 5,88 Miliar lembar
Didirikan: 2001 | IPO: 13 Januari 2025 (Brand New Public Company)
🟢 OVERVIEV & REKOMENDASI - BUY (IPO AGROKIMIA FOOD SECURITY, STRONG GROWTH TRAJECTORY, CAPACITY EXPANSION AGGRESSIVE, GOVERNMENT SUPPORT TAILWIND, DIVIDEN RESUMED, IPO MOMENTUM STRONG)h2
Rating: 🟢 BUY (Perusahaan agrokimia IPO baru dengan trajectory pertumbuhan kuat: Q1 2025 revenue pestisida +18.2% YoY, target 2025 profit +25% pertumbuhan dengan revenue 15-20% growth, kapasitas ekspansi agresif (3 pabrik pupuk baru Sumatra target 2029 = 700K ton dari 300K ton sekarang), methomyl produksi native 2H 2025 startup, dividen interim Rp 8.5 per lembar (2.45% yield) resumed, analyst target Rp 550 (+35% upside), IPO price Rp 230 sekarang Rp 408 (+77% YTD momentum kuat), government food security support strong, market penetration Indonesia masih rendah = huge runway - best untuk growth investor + IPO play + food security tailwind)
DGWG adalah perusahaan agrokimia terintegrasi Indonesia fokus food security dengan portfolio pestisida, pupuk, benih, alat pertanian. Q1 2025 revenue Rp 808M (est), pestisida segment +18.2% YoY ke Rp 291.4M (36% total revenue), volume +17.6%, ASP +0.5% stable. Pupuk segment terbesar dengan ekspansi agresif. Target 2025 full-year: revenue 15-20% growth base Rp 3.4T 2024, profit +25% growth dari laba bersih Rp 180M 2024 guidance ke Rp 225M+ 2025. H2 seasonality strong (musim hujan tinggi = hama serangan peak = pestisida demand spike). Capex expansion ambitious: 3 pabrik pupuk baru Sumatra hingga 2029 (+400K ton capacity), methomyl active ingredient production 2H 2025 (3.3K ton capacity) = supply chain control + margin improvement. Dividen interim Rp 8.5 per lembar announced (2.45% yield), first dividend signal. IPO price Rp 230, now Rp 408 (+77% YTD) = momentum exceptional, foreign buying accumulating (+4-6% foreign stake). P/E 12.8x reasonable for growth company. P/B 2.5x premium justified. Analyst consensus Samuel Rp 550 (+35% upside). Risk manageable: weather risk, delayed capex execution, competitive pressure. Rating BUY dengan target Rp 500-600 dalam 12-18 bulan (22-47% upside continuation).
Status Kini (Data Q1 2025, YTD 2025 Momentum) - IPO GROWTH INFLECTION:
| Item | Nilai | Status |
|---|---|---|
| IPO Price (Jan 13) | Rp 230 | Listing reference |
| Harga Saat Ini | Rp 408 | +77% YTD momentum ✓ |
| Q1 2025 Revenue | Rp 808 Miliar est | Solid start |
| Pestisida Segment | Rp 291.4 Miliar (+18.2% YoY) | Strong growth ✓ |
| Pestisida Volume | +17.6% YoY | Demand robust ✓ |
| Target 2025 Revenue | Rp 3.4-3.6 Triliun | 15-20% growth |
| Target 2025 Profit | Rp 225M+ | +25% YoY growth |
| Dividen Interim 2025 | Rp 8.5 per lembar | 2.45% yield ✓ |
| Analyst Target (Samuel) | Rp 550 | +35% upside |
| Kapasitas Pupuk | 300K ton current → 700K ton 2029 | Massive expansion ✓ |
| Methomyl Production | Start 2H 2025 (3.3K ton) | Supply chain control ✓ |
| Foreign Buying | +4-6% accumulation | Institutional interest ✓ |
| P/E (TTM) | 12.8x | Fair for growth |
| P/B Ratio | 2.5x | Premium justified |
| Momentum YTD | +77% | Exceptional |
Profil Agrokimia IPO Growth:
- ✓ IPO momentum exceptional - +77% since Rp 230 IPO price Jan 2025
- ✓ Revenue growth strong - Q1 +18.2% pestisida, 2025 target 15-20% total
- ✓ Profit growth acceleration - 2025 target +25% from Rp 180M baseline
- ✓ Capacity expansion aggressive - 3 plants Sumatra, 700K ton target 2029
- ✓ Supply chain integration - Methomyl production 2H 2025 = margin boost
- ✓ Dividen resumed - Rp 8.5 interim (2.45% yield) attractive
- ✓ Government support - Food security focus, farmer demand strong
- ✓ Analyst target visible - Rp 550 (+35% upside from current)
Kesimpulan Awal: DGWG adalah IPO AGROKIMIA GROWTH STORY - Food security mandate, revenue growth double-digit, profit inflection +25%, capacity expansion triple scale, government support strong, IPO momentum exceptional, dividen attractive, analyst target clear. Best untuk growth investor + IPO play + Indonesia agricultural transformation story.
ANALISIS FUNDAMENTAL - 5 PILAR (GROWTH INFLECTION CLEAR)h2
PILAR 1: PROFITABILITAS & MARGINh3
Status: ✓ GROWTH INFLECTION CLEAR, ACCELERATION VISIBLE
✓ 2025 profit target +25% YoY - Strong inflection from Rp 180M baseline.
✓ Q1 2025 pestisida +18.2% YoY - Healthy organic growth momentum.
✓ Volume growth +17.6%, ASP stable +0.5% - Quality growth visible (volume-driven).
✓ H2 seasonality strong - Musim hujan = peak demand pestisida expected.
✓ Methomyl production 2H 2025 - Supply chain control = margin expansion ahead.
Assessment: Profitability inflection clear = GROWTH ACCELERATION TRAJECTORY.
PILAR 2: ARUS KAS & PEMBIAYAANh3
Status: ✓ CAPEX-HEAVY BUT INTERNALLY FUNDED, HEALTHY BALANCE
✓ IPO capital raised - Rp 200M+ funding untuk capex, working capital.
✓ Capex aggressive 3 plants Sumatra - Phased 2025-2029, internally manageable.
✓ Operating cashflow strong - Revenue growth driving positive OCF.
✓ Dividen resumed - Rp 8.5 interim signals confidence in cashflow.
Assessment: Cashflow positioned well = SELF-FUNDING CAPACITY for expansion.
PILAR 3: UTANG & SOLVABILITASh3
Status: ✓ POST-IPO STRONG, BALANCE SHEET HEALTHY
✓ IPO capital boost - Reduced financial leverage risk.
✓ Debt levels manageable - Agro sector standard, no solvency stress.
✓ Current ratio healthy - Working capital adequate for growth phase.
✓ No bankruptcy risk - Solid balance sheet position.
Assessment: Solvency excellent = FINANCIAL FLEXIBILITY for capex.
PILAR 4: HASIL INVESTASI & RETURNh3
Status: ✓ IMPROVING RAPIDLY, CAPACITY RAMP WILL DRIVE ROIC
✓ ROE improving - Profit growth (+25% target) lifting returns.
✓ ROIC will expand 2026+ - New plants (Sumatra, methomyl) high-margin.
✓ Capital employed efficiently - Capex disciplined, revenue growth organic + inorganic.
✓ Dividend + capital appreciation - Dual return stream attractive.
Assessment: Returns rebuilding = STRONG INFLECTION TRAJECTORY 2026+.
PILAR 5: DIVIDEN & RETURN PEMEGANG SAHAMh3
Status: ✓ DIVIDEND RESUMED, CAPITAL APPRECIATION STRONG
✓ Dividen interim Rp 8.5 - 2.45% yield attractive for growth stock.
✓ IPO momentum +77% YTD - Capital appreciation exceptional.
✓ Expected return 30-40% - Dividen + growth upside strong.
✓ Stock at discount to analyst target - Rp 550 (+35% visible).
Assessment: Shareholder return = EXCELLENT combined dividen + growth.
RINGKASAN 5 PILARh2
| Pilar | Status | Nilai |
|---|---|---|
| 1. Profitabilitas | ✓ Growth inflection clear | 4/5 |
| 2. Arus Kas | ✓ Capex-heavy but funded | 3.5/5 |
| 3. Utang & Solvabilitas | ✓ Healthy post-IPO | 4/5 |
| 4. Return Investasi | ✓ Improving rapidly | 3.5/5 |
| 5. Dividen | ✓ Resumed 2.45% yield | 3.5/5 |
| RATA-RATA | ✓ IPO GROWTH STORY | 3.7/5 |
Score 3.7/5 Good (strong growth trajectory). IPO quality improving.
VALUASI & FAIR VALUEh2
Fair Value Estimation (Growth IPO Model):
| Model | Fair Value | Current (Rp 408) | Upside |
|---|---|---|---|
| P/E 14x (normalized 2025) | Rp 475-525 | Rp 408 | +16-29% |
| P/B 3.0x (growth premium) | Rp 550-650 | Rp 408 | +35-59% |
| PEG 0.5x (growth-adjusted) | Rp 500-600 | Rp 408 | +22-47% |
| Analyst consensus (Samuel) | Rp 550 | Rp 408 | +35% |
| Bull case (2027 capex ramp) | Rp 700-800 | Rp 408 | +72-96% |
🟢 CONSENSUS FAIR VALUE Rp 500-600 = Current Rp 408 at discount 15-32%.
SKENARIO 2-TAHUNh2
| Scenario | Probability | Return | Target | Narrative |
|---|---|---|---|---|
| Bull | 40% | +60% | Rp 653 | Capex ramp ahead schedule, profit +35%, margins +300bp, methomyl production success |
| Base | 45% | +35% | Rp 550 | Steady growth, capex on-track, profit +25%, margins stable |
| Bear | 15% | -20% | Rp 326 | Capex delays, competitive intensity, margin pressure, weather risk |
| Expected | +32% | Rp 539 | Probability-weighted STRONG return |
🟢 Expected return +32% over 2Y + dividen 2-3% CAGR = 5-6% total return solid.
REKOMENDASI INVESTASIh2
RATING: 🟢 BUY (IPO Growth, Food Security Tailwind, Capacity Expansion, Analyst Target Clear)h3
🟢 BUY aggressively di Rp 408, ACCUMULATE di weakness Rp 380-395
Alasan BUY (Strong Conviction):
- ✓ IPO momentum exceptional +77% YTD (Rp 230 → Rp 408)
- ✓ Revenue growth strong Q1 +18.2% pestisida YoY
- ✓ Profit target +25% 2025 clear inflection
- ✓ Capacity expansion aggressive (3 plants, 700K ton 2029)
- ✓ Supply chain integration (methomyl 2H 2025)
- ✓ Government food security support tailwind
- ✓ Dividen resumed 2.45% yield attractive
- ✓ Analyst target Rp 550 (+35% visible)
- ✓ Foreign buying accumulating (quality signal)
- ✓ Market penetration Indonesia still low (runway huge)
Position Sizing:
| Investor | Strategy | Target |
|---|---|---|
| Growth + IPO Play | BUY 100% | Rp 500-600 exit |
| Income + Growth | BUY 50% | Rp 550 take profit |
Hold Period: 12-24 months (capex ramp, profit inflection visibility)
Key Catalysts (2026):
| Event | Timeline | Impact |
|---|---|---|
| 2025 full-year results | Feb 2026 | Confirm +25% profit growth guidance |
| Methomyl production ramp | Q2-Q3 2026 | Supply chain benefits visible in margin |
| First Sumatra plant groundbreaking | Q2-Q3 2026 | Capex execution confidence |
| 2026 guidance upgrade | May 2026 | Expect +20% profit growth 2026 |
| Dividen payment | Jun 2026 | Consistent dividen signal |
Exit Strategy:
| Level | Action | Timing |
|---|---|---|
| Rp 450-500 | HOLD, accumulate dips | Accumulation continues |
| Rp 550-600 | REDUCE 30-50% | Profit-taking partial |
| >Rp 700 | EXIT remaining | Fair value exceeded |
KOMPETITOR, ANCAMAN, PELUANGh2
Competitive Landscape (Agrokimia Indonesia):
DGWG competitor dengan BISI (Benih Industri), Syngenta, Corteva lokal. DGWG unique as diversified (pestisida + pupuk + alat) vs specialized competitors.
Ancaman (Manageable):
- 🟡 Competitive intensity (BISI, Syngenta have scale advantages)
- 🟡 Weather risk (drought = reduced pestisida demand)
- 🟡 Commodity price volatility (raw material input costs)
Peluang (Strong Government Support):
- 🟢 Food security mandate Indonesia (government priority)
- 🟢 Domestic market penetration (farmer adoption still growing)
- 🟢 Capacity expansion (Sumatra plants filling unmet demand)
- 🟢 Supply chain integration (methomyl production margin upside)
- 🟢 Export opportunities (ASEAN agricultural integration)
KESIMPULANh2
DGWG adalah 🟢 BUY - IPO AGROKIMIA DENGAN STRONG GROWTH TRAJECTORY + GOVERNMENT FOOD SECURITY SUPPORT.
Strengths:
- ✓ IPO momentum exceptional +77% YTD (strength signal)
- ✓ Revenue growth strong +18.2% Q1 pestisida
- ✓ Profit inflection clear +25% target 2025
- ✓ Capacity expansion aggressive (700K ton 2029 vs 300K now)
- ✓ Supply chain integration (methomyl 2H 2025)
- ✓ Government support strong (food security priority)
- ✓ Dividen resumed attractive (2.45% yield)
- ✓ Analyst target clear Rp 550 (+35% upside)
- ✓ Valuation fair P/E 12.8x for growth company
- ✓ Market opportunity huge (Indonesia farmer adoption low)
Weaknesses (Manageable):
- 🟡 IPO new (execution risk on capex projects)
- 🟡 Competitive pressure (BISI, Syngenta have scale)
- 🟡 Weather dependent (drought risk to demand)
- 🟡 Capex execution (3 plants on-time/budget)
Best For: Growth investor, IPO play, food security/Indonesia agricultural transformation believer, 12-24 month horizon, seeking 30-40% upside + 2-3% dividen.
Expected Return: +32% capital (2Y) + 2-3% dividen = 5-6% CAGR solid.
Recommendation: BUY DGWG aggressively at current Rp 408 - IPO growth trajectory clear, food security tailwind strong, capacity expansion ambitious, analyst target visible, momentum exceptional, dividen attractive. Target Rp 500-600 in 12-18 months (22-47% upside). Best entry opportunity is NOW during momentum consolidation post-IPO.
Analisis dibuat 7 Januari 2026 berdasarkan Q1 2025 performance, 2025 full-year guidance, IPO January 2025 context, capex expansion strategy, analyst consensus, dan momentum exceptional YTD +77%.
Comments